[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

ID24264A - Komposisi yang terdiri dari 5-[4-[2-(n-metil-n-2-piridil)amino) etoksi[benzil] tiazolidin-2,4-dion - Google Patents

Komposisi yang terdiri dari 5-[4-[2-(n-metil-n-2-piridil)amino) etoksi[benzil] tiazolidin-2,4-dion

Info

Publication number
ID24264A
ID24264A IDW991520A ID991520A ID24264A ID 24264 A ID24264 A ID 24264A ID W991520 A IDW991520 A ID W991520A ID 991520 A ID991520 A ID 991520A ID 24264 A ID24264 A ID 24264A
Authority
ID
Indonesia
Prior art keywords
ethocysie
tiazolidin
dion
benzil
pyridyl
Prior art date
Application number
IDW991520A
Other languages
English (en)
Indonesian (id)
Inventor
Jeffrey Roger Granett
Original Assignee
Smithkline Beecham P L C Cs
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9712851.6A external-priority patent/GB9712851D0/en
Application filed by Smithkline Beecham P L C Cs filed Critical Smithkline Beecham P L C Cs
Publication of ID24264A publication Critical patent/ID24264A/id

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Diabetes (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Hematology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Obesity (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)
IDW991520A 1997-06-05 1998-06-02 Komposisi yang terdiri dari 5-[4-[2-(n-metil-n-2-piridil)amino) etoksi[benzil] tiazolidin-2,4-dion ID24264A (id)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB9711683.4A GB9711683D0 (en) 1997-06-05 1997-06-05 Composition
GBGB9712851.6A GB9712851D0 (en) 1997-06-18 1997-06-18 Composition
PCT/EP1998/003478 WO1998055122A1 (en) 1997-06-05 1998-06-02 Composition comprising 5-[4-[2-(n-methyl-n-2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione

Publications (1)

Publication Number Publication Date
ID24264A true ID24264A (id) 2000-07-13

Family

ID=26311662

Family Applications (1)

Application Number Title Priority Date Filing Date
IDW991520A ID24264A (id) 1997-06-05 1998-06-02 Komposisi yang terdiri dari 5-[4-[2-(n-metil-n-2-piridil)amino) etoksi[benzil] tiazolidin-2,4-dion

Country Status (29)

Country Link
EP (1) EP0998284A1 (hu)
JP (1) JP2001521553A (hu)
KR (1) KR20010013410A (hu)
CN (3) CN1526391A (hu)
AP (1) AP1214A (hu)
AR (2) AR015120A1 (hu)
AU (1) AU8215098A (hu)
BG (1) BG104048A (hu)
BR (1) BR9810405A (hu)
CA (2) CA2292629C (hu)
CO (1) CO4940400A1 (hu)
DZ (1) DZ2510A1 (hu)
EA (1) EA002384B1 (hu)
GB (1) GB9711683D0 (hu)
HU (1) HUP0004070A3 (hu)
ID (1) ID24264A (hu)
IL (1) IL133074A0 (hu)
MX (1) MXPA99011322A (hu)
NO (2) NO995938L (hu)
NZ (2) NZ523725A (hu)
OA (1) OA11306A (hu)
PE (1) PE78899A1 (hu)
PL (1) PL337201A1 (hu)
SK (1) SK164899A3 (hu)
TR (2) TR199902963T2 (hu)
TW (1) TW570797B (hu)
UY (1) UY25032A1 (hu)
WO (1) WO1998055122A1 (hu)
ZA (2) ZA984826B (hu)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20010040A1 (es) 1999-04-23 2001-03-10 Smithkline Beecham Plc Polimorfo de sal del acido maleico de 5-[4-[2-(n-metil-n-(2-piridil)amino)etoxi]bencil]-tiazolidina-2,4-diona
US20040248945A1 (en) 1999-04-23 2004-12-09 Smithkline Beecham P.L.C. Thiazolidinedione derivative and its use as antidiabetic
ATE246191T1 (de) 1999-04-23 2003-08-15 Smithkline Beecham Plc Polymorph von 5-(4-(2-(n-methyl-n-(2- pyrdyl)amino)äthoxy)benzyl)thiazolidin-2,4-dion maleinsäuresalz
GB0021978D0 (en) 2000-09-07 2000-10-25 Smithkline Beecham Plc Novel pharmaceutical
GB0127805D0 (en) * 2001-11-20 2002-01-09 Smithkline Beecham Plc Pharmaceutical composition
AU2002350965A1 (en) * 2001-12-13 2003-06-23 Smithkline Beecham Plc Toluenesulfonate hydrates of a thiazolidinedione derivative
GB0129876D0 (en) * 2001-12-13 2002-02-06 Smithkline Beecham Plc Novel pharmaceutical
GB0129871D0 (en) * 2001-12-13 2002-02-06 Smithkline Beecham Plc Novel pharmaceutical
GB0130509D0 (en) * 2001-12-20 2002-02-06 Smithkline Beecham Plc Novel pharmaceutical
US7435741B2 (en) 2006-05-09 2008-10-14 Teva Pharmaceutical Industries, Ltd. 2-N{5-[[4-[2-(methyl-2-pyridinylamino) ethoxy] phenyl]methyl]-2,4-thiazolidinedione} butanedioic acid, methods of preparation and compositions with rosiglitazone maleate
DE06252444T8 (de) * 2006-05-09 2009-03-19 Teva Pharmaceutical Industries Ltd. 2-N-{5-[[4-[2-(Methyl-2-pyridinylamino)-ethoxy]-phenyl]-methyl]-2,4-thiazolidindion}-bernsteinsäure, Verfahren zur Herstellung und Zusammensetzungen mit Rosiglitazonmaleat
WO2015008234A1 (en) * 2013-07-17 2015-01-22 Glenmark Pharmaceuticals S.A. Bicyclic heterocyclic compounds as ror gamma modulators

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3856378T2 (de) * 1987-09-04 2000-05-11 Beecham Group P.L.C., Brentford Substituierte Thiazolidindionderivate
GB9218830D0 (en) * 1992-09-05 1992-10-21 Smithkline Beecham Plc Novel compounds
WO1995021608A1 (en) * 1994-02-10 1995-08-17 Smithkline Beecham Plc Use of insulin sensitisers for treating renal diseases
KR19990036290A (ko) * 1995-08-10 1999-05-25 로즈 암스트롱 비인슐린 의존성 진성 당뇨병 환자에 대한 외인성 인슐린 투여량의 감소 방법
AU7604596A (en) * 1995-11-17 1997-06-11 Warner-Lambert Company A method of treating myotonic dystrophy
NZ314406A (en) * 1996-03-18 2000-12-22 Sankyo Co Treatment or prophylaxis of pancreatitis with a medicament containing an insulin sensitiser including oxazoles and thiazoles
EP0921798A1 (en) * 1996-07-12 1999-06-16 Smithkline Beecham Plc Novel treatment of leptine resistance

Also Published As

Publication number Publication date
JP2001521553A (ja) 2001-11-06
NO995938D0 (no) 1999-12-03
EA199901116A1 (ru) 2000-06-26
PL337201A1 (en) 2000-08-14
AR015120A1 (es) 2001-04-18
BR9810405A (pt) 2000-08-29
AP1214A (en) 2003-10-08
WO1998055122A1 (en) 1998-12-10
CN1430959A (zh) 2003-07-23
CA2292629A1 (en) 1998-12-10
AU8215098A (en) 1998-12-21
IL133074A0 (en) 2001-03-19
PE78899A1 (es) 1999-10-22
CA2292629C (en) 2004-01-06
KR20010013410A (ko) 2001-02-26
BG104048A (bg) 2000-07-31
NZ513922A (en) 2001-09-28
ZA984826B (en) 1999-08-03
NZ523725A (en) 2004-09-24
CO4940400A1 (es) 2000-07-24
UY25032A1 (es) 1998-11-26
HUP0004070A2 (hu) 2002-02-28
SK164899A3 (en) 2000-11-07
ZA9811572B (en) 1999-07-22
DZ2510A1 (fr) 2003-01-25
TR199902963T2 (xx) 2000-02-21
TR200002790T2 (tr) 2001-11-21
CN1259050A (zh) 2000-07-05
AP9901696A0 (en) 1999-12-31
EA002384B1 (ru) 2002-04-25
TW570797B (en) 2004-01-11
NO995938L (no) 2000-02-02
CN1526391A (zh) 2004-09-08
CN1112926C (zh) 2003-07-02
HUP0004070A3 (en) 2002-03-28
GB9711683D0 (en) 1997-08-06
AR008198A1 (es) 1999-12-29
MXPA99011322A (es) 2004-12-02
OA11306A (en) 2003-10-22
EP0998284A1 (en) 2000-05-10
CA2333352A1 (en) 1998-12-10
NO20040738L (no) 2000-02-02

Similar Documents

Publication Publication Date Title
DE69718480D1 (de) Heterocyclische metalloprotease inhibitoren
ATE267805T1 (de) Lactamverbindungen als metalloprotease- inhibitoren
ATE226573T1 (de) Heterozyklische metalloproteaseinhibitoren
IS5338A (is) Ný spíróasabísýklísk heterósýklísk efnasambönd
ATE485283T1 (de) Inhibitoren der 11-beta-hydroxy-steroid- dehydrogenase des typs 1
DE69940115D1 (de) Heterocyclische inhibitoren von p38
NO20021116D0 (no) Ny sammensetning
DE69830410D1 (de) Meta-benzamidinderivate als serinprotease-inhibitoren
DK1114051T3 (da) Inhibitorer for p38
MA26500A1 (fr) Forme nouvelle de s-omerprazole
EE200200132A (et) Uudsed spiroheterotsüklilised ühendid, mis on kasulikud tsüsteiinproteaaside pöörduvate inhibiitoritena
NO20021115D0 (no) Ny sammensetning
ID24264A (id) Komposisi yang terdiri dari 5-[4-[2-(n-metil-n-2-piridil)amino) etoksi[benzil] tiazolidin-2,4-dion
ATE333866T1 (de) Lipasehemmer enthaltende dispersionsformulierungen
DK0928291T3 (da) 3-Mercaptoacetylamino-1,5-substituerede 2-oxo-azepanderivater, der er nyttige som inhibitorer af matrixmetalloproteinase
ID24677A (id) Kombinasi senyawa aktif fungisidal
ID24267A (id) Enansiomer-enansiomer dari 4-[[(sianoimino) [(1,2,2-trimetilpropil) amino] metil] amino] benzonitril
DK199901730A (da) Ny Sammensætning
DK0888340T3 (da) 4-(benzo-1,3-dioxolyl)-pyrrolidin-3-carboxylsyre-derivater som antagonister for enodthelin
ID24081A (id) Senyawa-senyawa 5-(2-imidazolinilamino) benzimidazol yang berguna sebagai agonis-agonis alfa-2-adrenoseptor
ATE525362T1 (de) 2-(3-(4-(2-t-butyl-6-trifluormethylpyrimidin-4-
DK0944601T3 (da) Heterocykliske quanidinylaminoforbindelser som alfa-2-adrenoceptoragonister
DK1150976T3 (da) 3-(Thiosubstituerede amido)lactamer, der er nyttige som inhibitorer af matrixmetalloproteinase
ID18481A (id) 2-(3,5-difluorofenil)-3-(4-metilsulfonil)fenil)-2-siklopenten-1-on yang berguna sebagai inhibitor cox-2
AU7673800A (en) Hydrated N-(3-((2-(3,4-dimethoxyphenyl) ethyl) amino) propyl) -4-nitro benzamidehydrochloride and its use in pharmaceutical compositions